Otro tratamiento esperanzador para pacientes con melanomas braf negativos...

Combination Therapy Using Interleukin-12 And Pembrolizumab Helps Shrink Tumors In Almost Half Of Melanoma Patients, Clinical Trial Shows.

STAT (11/8, Feuerstein) reports that a combination immunotherapy treatment consisting of OncoSec Medical's ImmunoPulse IL-12 and Merck's Keytruda (pembrolizumab) "is shrinking tumors in almost half of the skin cancer patients treated in a small clinical trial." OncoSec's approach "is to inject 'cold' melanoma lesions with DNA-based interleukin-12 (IL-12), a protein that activates components of the immune system." Then, a "short series of electric shocks (delivered with needles)" is used to "open the membrane of the tumor cells and help the IL-12 to enter." Of the 21 evaluable patients with melanoma "predicted to be unresponsive to checkpoint inhibitors based on findings from two biomarker assays," 9 patients, or 43%, "responded to the IL-12/Keytruda combination treatment," with 8 patients having a "complete response." The findings were presented at the Society of Immunotherapy for Cancer (SITC) annual meeting.

Benjamin Hidalgo-Matlock

Skin Care Physicians of Costa Rica

4000-1054

2208-8206

Please excuse the shortness of this message, as it has been sent from a mobile device.